HC Wainwright Comments on Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at HC Wainwright issued their FY2029 EPS estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $1.30 for the year. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

Several other research analysts have also issued reports on ALT. Stifel Nicolaus assumed coverage on Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price target on the stock. UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.83.

Altimmune Price Performance

Shares of ALT stock traded down $0.07 on Monday, reaching $6.93. 1,466,236 shares of the company were exchanged, compared to its average volume of 2,264,879. Altimmune has a one year low of $5.28 and a one year high of $14.84. The company has a market cap of $492.86 million, a price-to-earnings ratio of -4.47 and a beta of 0.22. The company has a 50-day moving average of $7.88 and a 200-day moving average of $7.20.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter. During the same period in the prior year, the company earned ($0.39) earnings per share.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently added to or reduced their stakes in ALT. Dimensional Fund Advisors LP raised its stake in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after purchasing an additional 335,444 shares during the period. Bellevue Group AG raised its position in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after acquiring an additional 263,660 shares during the period. Virtu Financial LLC purchased a new position in Altimmune in the third quarter valued at about $674,000. Exchange Traded Concepts LLC grew its position in shares of Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock valued at $1,331,000 after acquiring an additional 92,498 shares during the period. Finally, Barclays PLC increased its stake in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock worth $956,000 after purchasing an additional 75,064 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.